We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
+10.88%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.53B
AUM Growth
+$250M
(+20%)
Cap. Flow
+$85.3M
Cap. Flow
% of AUM
5.59%
Top 10 Holdings %
Top 10 Hldgs %
55.98%
Holding
48
New
9
Increased
18
Reduced
6
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viatris
VTRS
|
+$36.9M |
| 2 |
GHDX
Genomic Health, Inc.
GHDX
|
+$26M |
| 3 |
KERX
Keryx Biopharmaceuticals Inc
KERX
|
+$24.8M |
| 4 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$23.1M |
| 5 |
WW
WW International
WW
|
+$18.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$41.2M |
| 2 |
Tenet Healthcare
THC
|
+$36.2M |
| 3 |
HOLX
Hologic
HOLX
|
+$32.3M |
| 4 |
UnitedHealth
UNH
|
+$24.6M |
| 5 |
Abbott
ABT
|
+$23.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 68.72% |
| 2 | Miscellaneous | 30.16% |
| 3 | Consumer Discretionary | 1.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AMRN
26
Amarin Corp
AMRN
$294M
| $19.4M | 1.27% |
550,000
| – | – |
|
|
WW
27
DELISTED
WW International
WW
| $17.1M | 1.12% |
+850,000
| New | +$18.2M |
|
28
ICU Medical
ICUI
$3.9B
| $16.9M | 1.11% |
+277,583
| New | +$16.4M |
|
|
BRLI
29
DELISTED
BIO-REFERENCE LABS INC-NEW-
BRLI
| $16.4M | 1.08% |
+543,724
| New | +$15M |
|
30
Geron
GERN
$842M
| $16.1M | 1.05% |
5,290,000
+317,400
| +6% | +$663K |
|
|
TRNX
31
DELISTED
TORNIER N V SHARES (NLD)
TRNX
| $13.4M | 0.88% |
573,655
-40,000
| -7% | -$831K |
|
|
GNMK
32
DELISTED
GenMark Diagnostics, Inc
GNMK
| $12.3M | 0.81% |
908,100
| – | – |
|
33
Bruker
BRKR
$8.49B
| $12.1M | 0.8% |
+500,000
| New | +$10.9M |
|
|
CRDC
34
DELISTED
CARDICA INC COM NEW (DE)
CRDC
| $9.55M | 0.63% |
+837,485
| New | +$8.5M |
|
35
Protalix BioTherapeutics
PLX
$214M
| $7.3M | 0.48% |
200,000
| – | – |
|
36
Gyre Therapeutics
GYRE
$709M
| $7.04M | 0.46% |
1,981
| – | – |
|
|
RPRX
37
DELISTED
Repros Therapeutics Inc.
RPRX
| $6.75M | 0.44% |
+390,370
| New | +$6.36M |
|
38
AngioDynamics
ANGO
$648M
| $6.26M | 0.41% |
383,630
-28,300
| -7% | -$410K |
|
|
BIOL
39
DELISTED
Biolase, Inc.
BIOL
| $5.97M | 0.39% |
217
| – | – |
|
|
CCRN
40
DELISTED
Cross Country Healthcare
CCRN
| $5.2M | 0.34% |
797,842
+489,300
| +159% | +$3.23M |
|
41
Orthofix Medical
OFIX
$370M
| $4.3M | 0.28% |
+118,683
| New | +$3.84M |
|
|
42
Abbott
ABT
$177B
| – | – |
-600,000
| Closed | -$23.1M |
|
|
HOLX
43
DELISTED
Hologic
HOLX
| – | – |
-1,500,000
| Closed | -$32.3M |
|
44
Humana
HUM
$47.6B
| – | – |
-200,000
| Closed | -$22.5M |
|
|
45
UnitedHealth
UNH
$337B
| – | – |
-300,000
| Closed | -$24.6M |
|
|
MNK
46
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| – | – |
-650,000
| Closed | -$41.2M |
|
|
MNTA
47
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| – | – |
-400,000
| Closed | -$4.66M |
|
|
NXTM
48
DELISTED
NxStage Medical Inc.
NXTM
| – | – |
-820,535
| Closed | -$10.5M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q2 2014 Portfolio in Review
As of Q2 2014, Camber Capital Management held 48 positions worth $1.53B, up 20% from $1.28B the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Camber Capital Management deployed $85.3M of net new capital in Q2 2014, opening 9 new positions and adding to 18 existing holdings. Its largest new stake was Achillion Pharmaceuticals: 5,800,000 shares worth $43.9M.
By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 75% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.
On the sell side, the largest reduction was Tenet Healthcare, an estimated $36.2M trimmed.
- Camber Capital Management's largest Q2 2014 buy was Achillion Pharmaceuticals: 5,800,000 shares worth $43.9M.
- Camber Capital Management added most to Viatris in Q2 2014, an estimated $36.9M increase.
- Camber Capital Management's biggest Q2 2014 reduction was Tenet Healthcare, cutting an estimated $36.2M.
- Camber Capital Management fully exited MALLINCKRODT PUBLIC LIMITED COMPANY in Q2 2014, selling an estimated $41.2M.
- Camber Capital Management's ten largest holdings make up 56% of its $1.53B portfolio in Q2 2014.
- Camber Capital Management opened 9 new positions and closed 7 in Q2 2014.
- Camber Capital Management's portfolio value rose 20% quarter-over-quarter to $1.53B.
Based on Camber Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.